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Abstract
Background: Alzheimer’s disease (AD) is an age-related neurodegenerative disorder associated with brain innate
immune activation mainly mediated by microglia. These cells are known to be activated in the brain of AD
patients and to produce inflammatory cytokines and neurotoxic molecules in response to Amyloid beta (Ab).
Activation of microglia can also promote Ab clearance via Toll-like receptors (TLRs). Myeloid differentiation factor 88
(MyD88) is the adaptor molecule for most of these innate immune receptors, transducing the intracellular signal
from TLRs to nucleus.
Results: Here, we report that more than 50% reduction in MyD88 expression in a mouse model of AD accelerated
spatial learning and memory deficits. Brain of APPswe/PS1-MyD88
+/- mice was characterized by a delay in
accumulation of Ab plaques and increased soluble levels of Ab oligomers. Furthermore, inflammatory monocyte
subset and brain IL-1b gene expression were significantly reduced in APPswe/PS1 mice with impaired MyD88
signaling.
Conclusions: These data indicate that activation of MyD88 intracellular signaling pathway, likely by TLRs, acts as a
natural innate immune mechanism to restrict disease progression of APPswe/PS1 mice.
Introduction
Alzheimer’s disease (AD) is the most common neuro-
degenerative pathology related to aging that results in
progressive neuronal death and memory loss. Neuro-
pathologically, this disease is characterized by the pre-
sence of both neurofibrillary tangles and plaques
composed of aggregates of amyloid-b (Ab)p r o t e i n ,a
proteolytic fragment derived from the amyloid precur-
sor protein (APP). As described by the amyloid cascade
hypothesis, AD pathogenesis is associated with altera-
tions in Ab homeostasis resulting in an accumulation
of Ab peptides within the brain parenchyma that may
exert neurotoxic effects and neuronal death [1]. His-
torically, amyloid plaques were correlated with cogni-
tive deficits. Accumulating evidences suggest that
soluble, oligomeric and even intracellular, rather than
insoluble deposits of Ab, correlate more strongly with
dementia severity [2].
Inflammation is an important pathological component
in the brains of AD patients. As proposed by the inflam-
mation hypothesis of AD, the neurodegenerative process
could be exacerbated by a chronic inflammatory response
to Ab peptides. Fibrillar Ab deposits in AD brains are
accompanied by innate immune responses such as acti-
vated microglia and increased levels of cytokines [1].
Microglia are the brain’s tissue macrophages and the pri-
mary immune effectors within the CNS that respond to
many pathological events. They are highly dynamic and
respond rapidly to perturbations within the brain [3,4].
Accumulating evidence supports the hypothesis that
microglia responses play a pivotal role in the pathogen-
esis of AD; however, their exact roles have not been yet
resolved. Microglial activation is associated with produc-
tion of neurotoxic mediators and inflammatory cytokines
that can lead to neuronal death and may contribute to
chronic neurodegenerative conditions [5]. On the other
hand, microglia can phagocyte Ab, produce Ab degrading
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from the brain [6]. The molecular mechanisms by which
t h ei n n a t ei m m u n es y s t e mm o d ulates the progression of
AD are not well understood. A better understanding of
the processes that regulate microglial activation may
enhance the possibility of finding therapeutic approach
against AD.
Toll-like receptors are transmembrane pattern recog-
nition receptors that act as sensor for specific elements
termed as pathogen-associated molecular pattern
(PAMPs). These receptors are involved in innate immu-
nity and inflammatory response by triggering activation
of immune cells. To date, 10 different functional TLRs
have been identified in humans and 12 in mice [7].
They display distinct ligand specificities and they are
known to bind many endogenous proteins [8]. Recent
work has implicated these receptors in microglial recog-
nition and response to Ab. Plaques associated-microglia
exhibit elevated TLR2, TLR4, TLR5, TLR7 and TLR9
mRNA levels [9]. Stimulation of microglia with innate
immune ligands for TLR2, TLR4 and TLR9 was found
to accelerate Ab clearance in vitro and in mouse model
of AD [10,11]. Mutations in TLRs, such as TLR4, are
risk factors for AD [12]. Ab can also directly bind TLR2
and TLR4 [13].
Taken together these studies argue for the involve-
ment of innate immune system and TLRs in the course
of AD, although the exact mechanisms mediating these
effects have yet to be uncovered. MyD88 bridges most
TLRs to the downstream signaling elements mitogen-
activated protein kinases (MAPKs) and nuclear factor-
kappaB (NF-B), which trigger transcriptional activation
of inflammatory genes [8]. MyD88 is also essential for
triggering expression of innate immune genes in micro-
glia following exposure to both exogenous and endogen-
ous toxic stimuli [14,15]. The aim of the present study
was therefore to determine the role of MyD88 in the
pathogenesis of AD. We thus generated a mouse model
of AD in a context of MyD88 deficiency. Our data from
t h e s em i c es u g g e s tac r i t i c a ln e u r o p r o t e c t i v er o l eo ft h e
MyD88 pathway in APPswe/PS1 mice.
Materials and methods
Transgenic mouse lines
APPswe/PS1 transgenic mice harbouring the human pre-
senilin I (A246E variant) and the chimeric mouse/human
Ab precursor protein (APP695swe) under the control of
independent mouse prion protein (PrP) promoter ele-
ments ([B6C3-Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J];
Jackson Laboratories) were bred with MyD88
-/- mouse
strain for at least three generations to generate APPswe/
PS1 mice heterozygous for the MyD88 gene. MyD88
-/-
mice (in C57BL/6 background) were provided by S. Akira
(Osaka University, Osaka, Japan). All newborn pups were
genotyped and included in the different experimental
groups. All mouse strains were maintained in a C57BL/6J
background and acclimated to standard laboratory con-
ditions. All protocols were conducted according to
the Canadian Council on Animal Care guidelines, as
administered by the Laval University Animal Welfare
Committee.
Fluorescent-activated cell sorting (FACS) analysis
To analyze the population of monocytes, anti-coagulated
whole blood was taken from the facial vein, quickly sus-
pended and cells were washed with DPBS with 4% of
fetal bovine serum (FBS). Cells were then re-suspended
into DPBS with 2% FBS and incubated on ice with puri-
fied rat anti-mouse CD16/CD32 (Mouse BD Fc Bloc,
BD Bioscience). Still on ice, the mix was incubated with
PE-Cy7 conjugated CD11b antibody (eBioscience), APC
conjugated CD115 antibody (eBioscience), PerCP cy5.5
conjugated Gr1 antibody (Cerdarlane) and CD45 PE-
Cy5 (BD Bioscience) for 45 minutes. Cells were washed
again in DPBS with 2% FBS. Red blood cells were lysed
with hemolysin according to manufacturer’sp r o t o c o l
(Beckman Coulter, Mervue, Galway, Ireland) and cells
were washed with DPBS and re-suspended in equal
volumes of DPBS. The cells were analyzed using a two-
lasers and six color FACS Canto II flow cytometer and
data acquisition was done with BD Facs Diva software
(Version 6.1.2, BD Biosciences, San Jose, CA). Cells
were sorted according to the different fluorescent anti-
bodies. Results were analyzed using Flow Jo software
(Tristar).
Tissue collection
To collect brain tissues for immunofluorescence, mice
were deeply anesthetized via an i.p. injection of a mix-
ture of ketamine hydrochloride and xylazine and then
were perfused intracardially with ice-cold 0.9% saline,
followed by 4% paraformadehyde in a 0.1 M borax buf-
fer (pH 9.5 at 4°C). Brains were rapidly removed from
skulls, post-fixed in PFA 1-3d at 4°C and cryoprotected
in 10% sucrose diluted in PFA overnight. The frozen
brains were then sectioned into 25-μm thick coronal
sections using a microtome (Cambridge Instruments
Company) and slices were collected in a cold cryopro-
tectant solution (0.05M sodium phosphate buffer, pH
7.3, 30% ethylene glycol, 20% glycerol, stored at -20°C).
For protein analysis, brains were decapitated, rapidly
removed from the skull and frozen in liquid nitrogen.
They were subsequently stored at -80°C until protein
extraction and detection.
Stereological analysis
To stain Ab plaques, free-floating sections were treated
30 min with a permeabilization/blocking solution
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bovine serum albumin (BSA; Sigma-Aldrich) in KPBS.
Using the same solution, sections were immunostained
60 min with monoclonal anti-Ab (6E10, 1:3,000; Chemi-
con international), washed three times for 5 min in
KPBS and then incubated with secondary antibody goat
anti-mouse Cy3 conjugated (1:1,000; Jackson Immunore-
search Laboratories, inc) for 60 min. Stereological analy-
sis was performed as described previously [16]. The
contours of the cortex and hippocampus areas were
traced as virtual overlay on the steamed images and
areas was calculated. For 3 and 6-month-old APP mice,
the area occupied by all Ab-labeled plaques was deter-
mined. For the analysis of 9-month-old APP mouse pla-
ques, the Stereo Investigator software (Microbrightfield)
sequentially chose counting frame in cortex and hippo-
campus. Areas of analyzed hippocampal or cortex region
were calculated as well as areas occupied by plaques in
those counting frames.
Protein extraction
Proteins from hemi-forebrains were extracted using a
modified method of the procedure published by Lesne
et al. [17]. All manipulations were done on ice to mini-
mize protein degradation. One hemi-forebrain was
placed in a 1 ml syringe with a 20 G needle. 500 μlo f
buffer A (50 mM Tris-HCl pH 7.6, 0.01% NP-40,
1 5 0m MN a C l ,2m ME D T A ,0 . 1 %S D S ,1m Mp h e n y l -
methylsulfonyl fluoride (PMSF), protease inhibitor cock-
tail) were added and 10 up and down were made to
homogenize the tissue, followed by a 5 minutes centrifu-
gation at 3 000 RPM at 4°C. The supernatant (extracel-
lular proteins enriched fraction) was then collected and
frozen at -80°C. The insoluble pellet was suspended in
500 μl TNT-buffer (Buffer B; 50 mM Tris-HCl pH 7.6,
150 mM NaCl, 0.1% Triton X-100, 1 mM PMSF, pro-
tease inhibitor cocktail), followed by a 90 minutes cen-
t r i f u g a t i o na t1 30 0 0R P Ma t4 ° C .T h es u p e r n a t a n t
(cytoplasmic proteins enriched fraction) was then col-
lected and frozen at -80°C. The pellet was suspended in
500 μl buffer C (50 mM Tris-HCl pH 7.4, 150 mM
N a C l ,0 . 5 %T r i t o nX - 1 0 0 ,1m ME G T A ,3 %S D S ,1 %
deoxycholate, 1 mM PMSF, protease inhibitor cocktail)
and incubated at 4°C, 50 RPM, for 1 hour. The samples
were centrifuged for 90 minutes at 13 000 RPM and 4°C
and the supernatant (membrane proteins enriched frac-
tion) was collected and frozen at -80°C. Protein concen-
tration of each fraction was determined using the
Quantipro BCA assay kit (Sigma) according to the man-
ufacturer protocol.
Detection of total Ab levels by Western blot
For total Ab detection by Western blot, 10-30 μgo f
extracellular protein fractions were separated on a
precast 10-20% SDS polyacrylamide Tris-Tricine gel
(Bio-Rad). Separated proteins were then transferred
onto polyvinylidene fluoride (PVDF) membranes (Perki-
nElmer Life and Analytical Sciences) and detected by
Western blotting. Blots were probed with a mouse anti-
amyloid beta protein monoclonal antibody clone 6E10
(1:1000, Covariance) in Tris-buffered saline with 0.05%
Tween 20 (TBS-T) and 5% skim milk. Blots were visua-
lized using anti-mouse secondary antibody tagged with
horseradish peroxidase (1:1000; Jackson Immuno-
Research) and ECL Plus Detection Reagents (GE Health-
care). Membranes were stripped in 25 mM glycine-HCl,
pH 2.0, containing 1% SDS to allow b-actin revelation
using first a mouse b-actin antibody (MAB1501, 1:10
000; Millipore Bioscience Research Reagents) and then a
goat anti-mouse peroxidase conjugated secondary anti-
body (1:10 000; Jackson ImmunoResearch). Semi-quanti-
tative analysis of signal was performed under a
Northern Light Desktop Illuminator (Imaging Research)
using a Sony Camera Video System and the NIH Image
J software version 1.32J. Optical values were normalized
according to the b-actin loading control.
RNA extraction and quantitative real-time PCR (Q-PCR)
Tissue samples were homogenized in Qiazol buffer
(Qiagen) and extracted using the RNeasy mini kit with
on-column DNase (Qiagen) treatment following the
manufacturer’s recommendations. RNA concentration
was measured using a NanoDrop spectrophotometer
(Thermo Scientific) and quality was assessed with an
Agilent 2100 Bioanalyzer (Agilent Technologies Inc).
First-strand cDNA synthesis was accomplished using
5 μg of isolated RNA in a reaction containing 200 U of
Superscript III Rnase H-RT (Invitrogen Life Technolo-
gies), 300 ng of oligo-dT18, 50 ng of random hexamers,
50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM MgCl2,
500 μM deoxynucleotides triphosphate, 5 mM dithio-
threitol, and 40 U of Protector RNase inhibitor (Roche
Diagnostics) in a final volume of 50 μl. The reaction
was performed at 25°C for 10 minutes following at 50°C
for 1 hour and then treated with 1 μgo fR N a s eAf o r
30 min at 37°C. The resulting products were purified
with Qiaquick PCR purification kits (QIAGEN). cDNA
corresponding to 20 ng of total RNA was used to per-
form fluorescent-based Realtime PCR quantification
using the LightCycler 480 (Roche). The following sets
of sense/antisense primers were used: for MyD88:
5’-TCCGGCAACTAGAACAGACAGACT-3’/5’-GCGG
CGACACCTTTTCTCAAT-3’,I L - 1 b:5 ’- TCAAATCT
CGCAGCAGCACATC-3’/5’-CCAGCAGGTTATCAT-
CATCATCCC-3’,1 8 S :5 ’-TGGATACCGCAGCTAGGA
ATAATG-3’/5’-TCACCTCTAGCGGCGCAATAC-3’,
Hprt1: 5’-CAGGACTGAAAGACTTGCTCGAGAT-3’/
5’-CAGCAGGTCAGCAAAGAACTTATAGC-3’.
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obtained from the same company and was used as
described by the manufacturer. The conditions for PCR
reactions for 45 cycles were: denaturation at 95°C for
10 sec, annealing at 60°C for 10 sec and elongation at
72°C for 12 sec. The reaction was then heated for 5 sec
at 2°C lower than the melting temperature of the DNA
fragment. Reading of the fluorescence signal was taken
at the end of the heating to avoid non-specific signal.
A melting curve was performed to assess non-specific
signal. Oligoprimer pairs that allow the amplification of
approximately 200 bp were designed by GeneTools soft-
ware (Biotools Inc) and their specificity was verified by
blast in the GenBank database. Data calculation and
normalization was performed using second derivative
method as described previously [18] using the reference
genes hypoxanthine guanine phosphoribosyl transferase
1 (Hprt1) and 18S ribosomal RNA (18S). PCR amplifi-
cation efficiency was verified.
Behavioral analysis
Mice were housed four or five per cage in a colony
maintained in a room under natural lighting conditions
with a 14/10 hr light-dark cycle (on at 6:00) and tested
during the “light on” phase of the day. Food and water
were provided ad libitum. Behavioral experimenter was
blinded to the genotype of animals. The behavioral and
general health of mice was monitored using a modified
version of the primary observation screen described by
the SHIRPA protocol [19]. The spatial learning abilities
of mice were assessed in the T-water maze task (TWM).
The T-maze apparatus (length of stem 64 cm, length of
arms 30 cm, width 12 cm, height of walls 16 cm) was
made of clear fiberglass and filled with water (23 ± 1°C)
at a height of 12 cm. An escape platform (11×11 cm)
was placed at the end of the target arm and was sub-
merged 0.5 cm below the surface. The acquisition phase
allows to evaluate animals for left-right spatial learning.
During the first two trials, platforms were placed on
each arms of the TWM. In order to assess arm prefer-
ences, the least chosen arm was reinforced by water
escape. The mice were placed in the stem of the T maze
and choose to swim either left or right until they found
the submerged platform and escape to it, to a maximum
of 60 s. After reaching the platform, the mice were
allowed to stay on it for 20 s and then were immediately
placed back in the maze. If the animals did not find the
platform within this limit, they were gently guided onto
it. Repeated trials were presented on the same day up
to a maximum of 48 trials. A rest period of at least
10-15 min intervened between each block of 10 trials.
A mouse was considered to have learned the task when
it made no errors in a block of five consecutive trials.
The reversal learning phase was then conducted
48 hours later. During this phase the same protocol was
repeated, except that the mice were trained to find the
escape platform on the opposite side to that on which
they had learned on acquisition phase. Two measures
were taken: number of trials to reach the criterion (5 of
5 correct choices made on consecutive trials) and escape
latency.
Statistical analysis
All statistical analysis was performed using the SPSS
software (SPSS 15.0). Homogeneity of variance in our
different samples was performed with the Levene’st e s t
and p < 0.05 was set as the level of a significant
difference.
Results
Reduced expression of MyD88 adaptor protein in
APPswe/PS1 mice increased memory deficits
As the brain tissue macrophage, microglia expresses a
wide range of TLRs to detect exogenous and endogenous
ligands. It is now well known that microglia use these
receptors to recognize and phagocyte Ab peptides. We
and others previously demonstrated that the TLR2 is
necessary for the microglia to mount an inflammatory
reaction against Ab [13,20,21]. When stimulated, TLRs
activate intracellular signaling cascade via the adaptor
protein MyD88. We show here that MyD88 mRNA
expression is upregulated in response to Ab (Figure 1a).
Indeed, quantitative real-time PCR (Q-PCR) analysis of
6m o n t h - o l dA P P swe/PS1 mice revealed a significant
increase in MyD88 mRNA compared to WT littermates.
To study the role of this major signaling protein, we
attempted to breed the APPswe/PS1 mouse with the
MyD88 knockout mice, which share the same back-
ground. Unfortunately, APPswe/PS1 mice lacking the
MyD88 adaptor protein were not viable. APPswe/PS1
mice heterozygous for the MyD88 gene were therefore
used for further analyses. By 3 months of age, MyD88
mRNA levels in the brain of APPswe/PS1-MyD88
+/- mice
were reduced of 66% compared to those of APPswe/PS1
mice as determined by Q-PCR (Figure 1b). Arbitrary
values obtained for APPswe/PS1 and APPswe/PS1-MyD88
+/- groups were 4.90 ± 1.02 and 1.66 ± 0.11. As expected,
MyD88
-/- mice did not express any detectable MyD88
mRNA (arbitrary value: 0.18 ± 0.03).
We next evaluated APPswe/PS1-MyD88
+/- mice in the
T-water maze for behavioral evaluation. Hippocampus-
based spatial learning and memory was assessed by the
ability of mice to acquire (training session) and retrieve
(test session) spatial information as indicative of learning
and memory functions. Escape latency and mean of
trials to reach the hidden platform placed on one arm
o ft h em a z ew e r er e c o r d e d .M i c et h a th a v ef o u n da n d
climbed onto the hidden platform on five consecutive
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During the initial training session, all groups exhibited
comparable performance, as demonstrate by the num-
bers of errors (Figure 2a) and time spent (Figure 2c) to
learn the task. No significant differences in term of
swimming performance or motivation were detected
between each group of mice. We performed a probe
trial 48 h after completing the initial training to evaluate
t h ec o g n i t i v ef l e x i b i l i t yo fo u rd i f f e r e n tm o u s es t r a i n s .
The hidden platform was placed on the opposite arm of
Figure 1 Relative expression of MyD88 expression in the brain of different mouse strains. (a) MyD88 mRNA expression is upregulated in
6 month-old APPswe/PS1 mice compared to WT littermates. ** P < 0.05 (vs WT) (b) APPswe/PS1-MyD88
+/- mice expressed significantly lower level
of MyD88 mRNAs compared to APPswe/PS1 mice at 3 months of age. ## P < 0.01, ### P < 0.001 (vs MyD88
-/-); * P < 0.05 (vs APPswe/PS1). Data
are expressed as mRNA arbitrary units normalized with housekeeping genes Hprt1 and 18S. Error bars: SEM; n = 3-4. (Statistical analysis was
performed using Student’s t-test in (a) and a one-way ANOVA followed by a Bonferroni post-hoc test in (b)).
Figure 2 Reduced expression of the adaptor protein MyD88 in APPswe/PS1 mice accelerates spatial memory deficits in the T-water
maze paradigm. Mice were trained to reach the hidden platform on one arm of the T-water maze apparatus. (a) Number of trials and time
spent (c) to learn the task were measured. All different strains of each ages performed similarly. Spatial learning and memory of trained mice
was challenged 48 hours later (Reversal phase). Compared with APPswe/PS1 mice and their controls, APPswe/PS1-MyD88
+/- transgenic mice
showed a greater decline of spatial cognitive capacities measured by the number of errors (b) and time spent (d) to reach the platform. Error
bars represent SEM; n = 8-11; * P < 0.05 (vs WT and MyD88
-/-), ** P < 0.01 (vs WT and MyD88
-/-), *** P < 0.001 (vs WT and MyD88
-/-), # P < 0.05
(vs APPswe/PS1), ## P < 0.01 (vs APPswe/PS1), ### P < 0.001 (vs APPswe/PS1). (Statistical analysis was performed using one-way ANOVA followed
by a Bonferroni or Tamhane’s post-hoc test).
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maze. Both wild-type and MyD88
+/- mice showed
equally successful latency and number of trials to criter-
ion during the reversal task. Because of their behavioral
phenotype, APPswe/PS1 mice demonstrate signs of cog-
nitive deficits at 6 and 9 months of age compared to
controls. The decreased expression of MyD88 gene in
APPswe/PS1 transgenic mice resulted in a significant
decline in memory as indicated by longer latencies
(Figure 2d) and increased number of errors committed
(Figure 2b) to reach the platform during the probe trial,
compared to results obtained for APPswe/PS1 mice.
Those cognitive deficits began as early as 3 months
(5.7 ± 0.6 trials and 11.0 ± 0.5 seconds for APPswe/PS1
vs 14.2 ± 2.4 trials and 14.0 ± 1.3 seconds for APPswe/
PS1-MyD88
+/-) and evolved rapidly at 6 (13.0 ± 1.0 trials
and 13.5 ± 0.7 seconds for APPswe/PS1 mice vs 30.1 ± 3.5
trials and 18.9 ± 1.9 seconds for APPswe/PS1-MyD88
+/-
mice) and 9 months (18.4 ± 1.7 trials and 17.0 ± 1.9 sec-
onds for APPswe/PS1 vs 34.7 ± 3.7 trials and 22.0 ± 1.5
seconds for APPswe/PS1-MyD88
+/-). These results
demonstrate that the reduce expression of MyD88 in
APPswe/PS1 mice result in a greater cognitive deficit as
depicted by accelerated spatial memory impairment.
These data suggest that MyD88 signaling plays an impor-
tant role in microglia activati o ni no r d e rt of i g h ta g a i n s t
AD evolution.
Ab plaques accumulate slower in brains of
APPswe/PS1-MyD88
+/- mice while more soluble Ab is
detected
As amyloid plaques are a neuropathological marker of
AD, we compared amyloid plaque load in APPswe/PS1
and APPswe/PS1-MyD88
+/-.A b immunoreactivity was
measured with the monoclonal 6E10 antibody specific
for the fragment 1-17 a.a. of the human Ab peptide in
brain coronal section. Area of Ab deposits was evaluated
in the cortex and hippocampus by stereological analysis
in two similar sections per animal and percentage area
occupied by plaques was calculated (Figure 3a). At three
months of age, no statistically significant difference in
area occupied by plaques was observed between APPswe/
PS1 and in APPswe/PS1-MyD88
+/- mice (0.007 ± 0.002%
and 0.002 ± 0.0006%, respectively). At six and nine
months, Ab deposits were significantly lower in APPswe/
PS1-MyD88
+/- brains compared to their APPswe/PS1 lit-
termates (0.292 ± 0.054 vs 0.116 ± 0.021, 1.208 ± 0.135
vs 0.769 ± 0.075, 6 and 9 month-old APPswe/PS1 and
APPswe/PS1-MyD88
+/-, respectively).
Since Ab plaques did not correlate with cognitive defi-
cits, we decided to measure soluble levels of Ab species
in brains of 6 month-old mice - there is accumulating
evidence associating soluble Ab oligomers with cognitive
impairments [2,17,22,23]. The amounts of different Ab
species were analyzed in extracellular (Figure 3b), intra-
cellular (Figure 3c) and membrane-associated (Figure 3d)
enriched protein fractions by western blots, based on the
method developed by Lesne et al. [17]. Proteins from
wild-type animals were used as control to assess the spe-
cificity of the antibody and the signal was barely detect-
able in such a case (data not shown). In general, most Ab
oligomers were increased in the brain of APPswe/PS1-
MyD88
+/- mice compared to that of APPswe/PS1. Indeed,
there were significantly higher levels of Ab oligomers in
extracellular (1-, 6- and 12-mer), intracellular (3- and
6-mer) and membrane-associated (1-, 3-, 6-, 9-mer)
enriched proteins fractions. Levels of sAPPa levels and
APP full length (APPfl) were also significantly higher in
brains of APPswe/PS1-MyD88
+/- mice in intracellular and
membrane-associated enriched proteins, respectively.
T h e s ed a t ai n d i c a t et h a ts o l u b l eo l i g o m e r i cA b levels
increased while the amyloid-b plaque load decreased in
brains of AD mice that had down-regulated MyD88 gene
expression.
Inflammatory monocyte subset is decreased while
resident monocytes are increased in the blood of
APPswe/PS1-MyD88
+/- mice
It has been established that there is two principal blood
monocyte populations that possess different migratory
properties: the “inflammatory subset” which is character-
i z e db yaC X 3CR1
LoCCR2
+Gr1
+ phenotype and the
“resident subset” categorized by CX3CR1
HiCCR2
-Gr1
-
[24]. To evaluate if these two subsets of monocytes were
different in animals with reduced MyD88 protein, we
measured expression levels of Gr1 surface marker on
monocytes of 3-4 month-old mice. To analyze leukocytes
in blood cells, we included only cells that were positive
for CD45 (Figure 4a). Then, CD45
+CD11b
+CD115
+ cells
were selected and considered as the population of mono-
cytes (Figure 4b). There was no significant difference
between percentages of monocytes (Figure 4b) or CD45
+
cells (data not shown) among the 4 groups. Relative pro-
portions of Gr1
+ and Gr1
- cells were then evaluated in
the monocyte population (Figure 4c). There was signifi-
cantly less Gr1
+ and more Gr1
- cells in APPswe/PS1-
MyD88
+/- compared to APPswe/PS1 mice (61.27 ± 2.66%
vs 68.80 ± 2.04% and 39.58 ± 2.81% vs 31.26 ± 2.04%,
respectively). To evaluate the global difference between
these two populations of monocytes, the ratios of Gr1
+
monocytes on Gr1
- monocytes were calculated (Figure 4d).
These ratios revealed a significant decrease for APPswe/
PS1-MyD88
+/- mice compared to their APPswe/PS1
control (1.57 ± 0.19% vs 2.25 ± 0.21%, respectively).
These results suggest that MyD88 pathway has a signifi-
cant impact on blood monocyte populations in this
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Page 6 of 12Figure 3 Amyloid plaque load and soluble Ab levels in the brain of APPswe/PS1 in a context of partial MyD88 deficiency. Deposition of
Ab plaques is significantly more abundant in 6 and 9 month-old APPswe/PS1 compared to APPswe/PS1-Myd88
+/- mice (a).A b immunoreactivity
in cortex and hippocampus is shown in brain sections of 9 month-old APPswe/PS1 and APPswe/PS1-Myd88
+/- mice. Percentage of area covered
by plaques was quantified for mice of 3, 6 and 9 month-old, respectively. n = 9-10. (Two-way ANOVA was performed revealing a significant
interaction between factors age and genotype. The comparison of genotype for each age was performed by Student’s t-test). To detect soluble
Ab, western blot analysis on 10-20% Tris-Tricine denaturing polyacrylamide gels of extracellular (b), intracellular (c) and membrane-associated
(d) enriched proteins of 6 month-old mice were assessed using monoclonal 6E10 antibody to reveal the different species. Most of Ab oligomers
were significantly higher in the brains of APPswe/PS1-MyD88
+/- (AM) mice than that of APPswe/PS1 (A) in all protein fractions. Bands depicted
here were cut from the same membrane for each protein fraction. Values are expressed as optical densities (OD) in arbitrary units (a.u.) of Ab
normalized with b-actin. n = 4-7; Student’s t-test; * P < 0.05, ** P < 0.01, *** P < 0.001. Error bars: SEM. Scale bar = 500 μm.
Michaud et al. Molecular Neurodegeneration 2011, 6:5
http://www.molecularneurodegeneration.com/content/6/1/5
Page 7 of 12mouse model of AD, which exhibits increased amount of
the resident subset and a decreased level of inflammatory
monocytes in a context of partial MyD88 deficiency.
IL-1b gene expression is decreased in the brain of
APPswe/PS1-MyD88
+/- mice
We finally investigated the inflammatory status in the
brains of APPswe/PS1-MyD88
+/- mice by measuring the
mRNA levels of the pro-inflammatory cytokine IL-1b
(Figure 5). A significant increase in IL-1b gene expres-
sion was found in the brain of APPswe/PS1 mice, which
was essentially abolished in a context of MyD88 defi-
ciency. IL-1b gene expression levels were significantly
higher in APPswe/PS1 mice than all other groups of
mice ((6,84 ± 1,16 vs 4,00 ± 0,30 (WT), 3,77 ± 0,47
(MyD88
+/- ) and 4,04 ± 0,37 (APPswe/PS1-MyD88
+/-)).
These data suggest that MyD88 plays a very important
role to regulate IL-1b gene transcriptional activation in
presence of Ab in this mouse model of AD.
Discussion
Ab accumulation is suggested to be a key event leading
to development and progression of AD. Production of
these toxic proteins is associated with neuronal apopto-
sis, reactive astrocytes, activated microglia and produc-
tion of inflammatory molecules. Innate immune
response plays a crucial role in the course of AD. How-
ever, the exact role of activated microglia is still under
debate. These cells can releasen e u r o t o x i cm e d i a t o r so r
can be neuroprotective in promoting the clearance of
toxic Ab from the brain. Several lines of evidence have
shown that microglia activated via TLRs can induce
Figure 4 Flow cytometry analysis of blood monocyte subsets in WT, MyD88
-/-, APPswe/PS1 and APPswe/PS1-MyD88
+/- mice. Blood taken
from the facial vein of 3-4 month-old mice was analyzed by FACS with the following fluorescently-labeled antibodies: CD45, CD11b, CD115 and
Gr1. Leukocyte population is represented as cells in the CD45
+ gate (a). To analyze exclusively monocytes in CD45
+ cells, CD11b
hi and CD115
hi
(CD45
+CD11b
+CD115
+) cells were gated and the total percent for each group was quantified (b). No significant change in number of
monocytes was revealed. Representatives histograms of monocytes for each group and their mean relative Gr1
+ and Gr1
- values (c) showed
significantly less Gr1
+ and more Gr1
- monocytes in APPswe/PS1-MyD88
+/- mice compare with APPswe/PS1 mice. This difference is even more
noticeable while expressing the ratio of Gr1
+ on Gr1
- monocytes (d). Error bars: SEM; n = 3-5; *P < 0.05 (vs APPswe/PS1). (Statistical analysis was
performed using one-way ANOVA followed by a Dunnett’s or Tamhane’s post-hoc test).
Michaud et al. Molecular Neurodegeneration 2011, 6:5
http://www.molecularneurodegeneration.com/content/6/1/5
Page 8 of 12beneficial effects on AD progression. We have pre-
viously demonstrated that TLR2 is important to delay
the cognitive decline in a mouse model of AD [21]. The
role of TLR2 in microglial activation was also high-
lighted in the study from Jana et al. [20]. A small pro-
portion of microglia in APPswe/PS1 mice brain expresses
TLR2 mRNA, which is a reliable index of pro-inflamma-
tory signaling in myeloid cells [20,21]. Other induced
innate immune receptors in AD brains include CD14,
TLR4, TLR5, TLR7 and TLR9 [9,20,25-28]. Phagocytosis
of Ab by activated microglia is significantly increased in
presence of ligands that activate TLRs [11,29-31].
A functional interaction was also demonstrated between
fibrillar Ab1-42 peptides and the innate receptor CD14
and this interaction resulted in microglial activation
[25]. Furthermore TLR2, TLR4 and CD14 are involved
in fAb phagocytosis [13]. Activation of TLR/MyD88
pathway may therefore act as a natural defense mechan-
ism in presence of toxic Ab and restrict disease
progression.
Quantification of MyD88 mRNA revealed an upregu-
lation of this gene in response to Ab as depicted by a
significant increase in APPswe/PS1 mice compared to WT.
This suggests a potential function of this gene in AD. To
study the role of MyD88 in AD, we used MyD88 knock-
out mice. Unfortunately, APPswe/PS1 mice deficient in
MyD88 gene were not viable. This suggests that MyD88
signaling cascade acts as a natural defense mechanism to
prevent Ab toxicity in this transgenic model, even during
mouse development. However it will be important in
future studies to test the effects of MyD88 deficiency in
other mouse models of AD, because the possibility
remains that such a lethally depends on the mouse lines
used in this study.
Thus, we created APPswe/PS1 mice heterozygous for
the MyD88 gene. This model showed a significant
decreased expression of the MyD88 transcript. In our
previous report, we have shown that APPswe/PS1 mice
deficient in TLR2 expression accelerated spatial and
contextual memory impairments. Here, we demonstrate
that a reduction in MyD88 expression also induced such
behavioral impairments. Analysis of hippocampus-based
spatial working learning was assessed in T-water maze.
In this behavioral test, the submerged platform is the
positive reinforcement. Mice were first trained to learn
the position of the platform in the maze. Forty-eight
hours later their reversal learning abilities were then
challenged, as the submerged platform was placed at the
opposite side of the maze. APPswe/PS1-MyD88
+/- mice
were impaired in reversal training, as seen with a higher
delay and number of errors made to reach the criterion
compared to APPswe/PS1 mice. These data demonstrate
the importance of the MyD88-dependent pathway in a
context of memory impairment induced by Ab.
Area occupied by amyloid-b plaques was calculated in
the brain of APPswe/PS1-MyD88
+/- mice. We found that
disease severity demonstrated by behavioral impairment
in the T-water maze did not correlate well with plaque
load in the brain. Indeed, APPswe/PS1-MyD88
+/- mice
had fewer plaques at 6 and 9 months compared to
APPswe/PS1 mice. Historically, accumulation of Ab pla-
ques was indicative of AD progression in human and
mouse models. However, as mentioned above, accumu-
lating evidence suggests that soluble and small oligo-
meric forms of Ab within human brain is more closely
associated with disease severity [2]. Soluble Ab in differ-
ent protein pools has deleterious effects in the brain and
promotes disease progression by inducing changes in
synaptic functions, behavioral deficits and promoting
neuronal degeneration [32-34]. We were able to show
that partial MyD88 gene deletion caused significant
increases in soluble Ab species in extracellular, intracel-
lular and membrane-associated enriched protein pools.
Nevertheless, we cannot rule out the possibility that the
membrane-associated enriched proteins can also contain
insoluble Ab, because of the 3% SDS concentration used
in the buffer. Although sAPPa fragment is known to be
a neurotrophic factor when it is secreted in the extracel-
lular space [35,36], Ab has been shown to promote
microtubule transport impairments in neurons and sub-
sequently sequester sAPPa inside the cell and prevent
its secretion [37]. Accordingly, sAPPa fragment levels
were higher in intracellular proteins fractions of APPswe/
PS1-MyD88
+/- mice while there was no significant dif-
ference in extracellular-enriched proteins level.
Figure 5 Decreased IL-1b gene expression in the brain of
controls and APPswe/PS1-MyD88
+/- mice. Quantification of IL-1b
mRNA expression by Q-PCR of 6 month-old mice revealed
significant differences between the different mouse strains. Indeed,
higher brain IL-1b mRNA levels were found in APPswe/PS1 mice
compared to those measured in WT, MyD88
+/- and APPswe/PS1-
MyD88
+/- mice. Error bars: SEM; n = 4-7; *P < 0,05 (significantly
different from the other groups). (Statistical analysis was performed
using one-way ANOVA followed by a Bonferroni post-hoc test).
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as an inert reservoir of Ab, thus protecting neurons
f r o ms o l u b l eo l i g o m e r i cf o r m so fA b [38]. These data
regarding the plaque load are in agreement with our
previous study in the APPswe/PS1-TLR2
-/- mice that had
less Ab plaques than their control APPswe/PS1 litter-
mates [21]. As in APPswe/PS1-MyD88
+/- mice, memory
capacities did not correlate with plaque load in the
brain of APPswe/PS1-TLR2
-/- mice. TLRs and MyD88
s i g n a l i n gm a yh a v eam o r ed i r e c tr o l eo nt h ec l e a r a n c e
of soluble oligomeric Ab.
Analyze of blood monocyte subsets revealed changes
in APPswe/PS1 mice in a context of partial MyD88 defi-
ciency. These mice exhibited significant relative decrease
in Gr1
+ and increase in Gr1
- monocytes. Globally, there
was a 30% reduction in the ratio of Gr1
+/Gr1
- mono-
cytes in blood of APPswe/PS1-MyD88
+/- compared to
APPswe/PS1 mice. As explained earlier, inflammatory
monocytes (CX3CR1
LoCCR2
+Gr1
+) and resident mono-
cytes (CX3CR1
HiCCR2
-Gr1
-) seem to play opposite roles.
Inflammatory monocytes are recruited quickly to inflam-
matory sites and differentiate into tissue specific macro-
phages and dendritic cells, whereas resident monocytes
infiltrate tissues in an inflammation-independent fashion
[24]. This process has been described in different tissues
including brain in mouse models of multiple sclerosis
[39] and axonal injury [40]. Moreover, inflammatory
monocytes have also been shown to be the main precur-
sors for microglial cells under inflammatory conditions
of the CNS [41,42]. MCP-1 (CCL2) is a major chemio-
kine involved in the recruitment of monocytes in AD
patients [43,44] and in mouse models of this pathology
[45,46]. Since interaction between MCP-1 and its bind-
ing CCR2 receptor stimulates the mobilization of bone
marrow-derived inflammatory monocytes [47], a
decrease production of this chemokine may be the
mechanism underlying the 30% reduction in the ratio of
Gr1
+/Gr1
- monocytes in blood of APPswe/PS1-MyD88
+/-. In this regard, MyD88 signaling is essential for the
transcriptional activation of MCP-1 in response to bac-
terial ligands [15,48], brain injury [40] and endogenously
produced toxic proteins [14]. Moreover, MyD88-
deficient mice have impaired monopoiesis during
bacterial infection resulting in significant reduction in
blood, splenic and bone marrow progenitors of inflam-
matory monocytes [49]. This suggests an important role
for MyD88-mediated monocyte homeostasis under
inflammatory conditions.
On the other hand, it seems that inflammatory
CX3CR1
LoCCR2
+Gr1
+ monocytes differentiate prefer-
entially in M1-like macrophages while resident
CX3CR1
HiCCR2
-Gr1
- monocytes are likely to become
M2-like macrophages [50,51]. M1 macrophages are
known to have high phagocytic, proteolytic and
inflammatory functions while M2 is suggested to be an
anti-inflammatory subset, which is known to promote
functions such as tissue remodeling, angiogenesis and
matrix deposition [52]. M1-like macrophages would
therefore be more efficient to clear Ab from the brain in
a context of chronic inflammation induced by accumu-
lation of cerebral Ab.T a k i n gt h a ti n t oc o n s i d e r a t i o n ,a
decreased Gr1
+/Gr1
- ratio in the pool of available
monocytes of APPswe/PS1-MyD88
+/- mice may be asso-
ciated with less M1-like macrophages and more M2-like
cells and explain the higher levels of soluble Ab in brain
of APPswe/PS1-MyD88
+/- mice. However, such a possi-
ble mechanism has to be fully investigated.
Low IL-1b mRNA levels in the brain of APPswe/PS1-
MyD88
+/- mice compared to APPswe/PS1 provide evi-
dence that MyD88 is a critical molecule for the regula-
tion of such inflammatory pathway in response to Ab
accumulation. This cytokine is crucial to orchestrate the
inflammatory response by microglia [53] and a sustained
production of IL-1b was reported to be beneficial by
reducing Ab pathology in a mouse model of AD [54].
We consequently believe that the innate immune
response by microglia is compromised in a context of
MyD88 deficiency, which may prevent their adequate
activation to fight against and clear Ab peptides. These
data converge into a primary role of MyD88-signaling
pathway to act as a natural protective mechanism in
presence of toxic Ab.
In summary, we show here that MyD88 plays a signifi-
cant role in the evolution of AD. Partial MyD88 defi-
ciency worsens cognitive deficit in APPswe/PS1 mice, as
well as increases brain soluble oligomeric Ab. Moreover,
APPswe/PS1 mice deficient in MyD88 have reduced IL-
1b gene expression and altered blood monocyte home-
ostasis leading to a decrease in the inflammatory popu-
lation. Altogether, these results clearly demonstrate the
crucial role of functional MyD88 signaling and support
the importance of TLRs to prevent or delay AD
pathology.
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